Sendit.Money is a remittance entity. It argues that individuals sending or receiving money in emerging markets can face insecure processes, slow transaction times and incur high costs. Sendit.Money asserts that this is because non-fiat currencies are changed multiple times before they are received. The company aims to change this. Its prototype application for African markets was received amidst positive feedback. It is now building a cost-effective mobile wallet providing a secure and inexpensive way to send and receive money that also allows users to compare transfer fees of different remittance agents in real-time. Sendit.Money was shortlisted as Best Global start-up at the 2020 Wales Startup Awards. The company will build and launch its Most Valuable Product (MVP) in Q3 of 2021. It will also use the funding to begin work with an authorised entity to become an approved representative.
days to go:
Expired
investment:
£182,732
Wirex is a UK financial technology company that aims to bring crypto & fiat currencies together on one simple payments portal. The company is building a platform where buying, holding, saving and spending any digital and traditional currency is quick, easy and accessible. The Wirex app supports 12 fiat and 10 crypto currencies, operates in 130 countries, and has more than 3.1 million registered users. Wirex launched the first Visa crypto-enabled payments card in the world. It has a £3 billion cumulative transaction volume and plans to expand to the USA by end-2020. Wirex will use the investment to allow millions of its users to own a share of the brand.
days to go:
Expired
investment:
£3,703,120
C-Major is a medical technology company. It asserts that over 2 million people suffer a Needle Stick Injury (NSI) every year and are at risk of contracting blood-borne viruses such as Hepatitis and HIV. It aspires to resolve this crisis by bringing to market its patented medical device, Controlled Helical Retraction Device, to prevent NSIs. The company argues that the device contains a ‘Helical Track’ mechanism for controlled acceleration of the needle during retraction as well as a ‘Sealed Port’ to minimise any blood splatter. C-Major endeavours to disrupt the $5.5 billion safety syringe market with its product. It is backed by the UK 'Innovation Seed' fund. C-Major will use the investment to complete the final design of its product for manufacture and assembly ahead of a Series A funding round in 2021.
days to go:
Expired
investment:
£211,595
Anastasis Biotec (AB) is a company that is developing a human protein-based product, Syntana-4 (S-4), that inhibits Cancer Stem Cells (CSC) - the growth engine of cancer. The global cancer drug market was at ~$200 billion in 2019. S-4 will initially target use for patients with relapsed prostate cancer which caused 3.8% of global cancer deaths in 2018. The company asserts that S-4 will have low manufacturing costs, making it affordable, enabling ‘mass-market’ sales. AB has raised £450,000 in equity convertible loans and grants in 2019 & 2020, including an Innovate-UK award. It is also aiming to progress S-4 further in collaboration with the University of Chicago’s cancer stem cell therapeutics Research and development (R&D) program. The company will use the investment to complete lab-testing before starting clinical trials.
days to go:
Expired
investment:
£270,543
Wombat is an investment platform that encourages millenials in the UK, Europe and beyond to invest in some of the world’s best-known brands for as little as £10. Their mission is to empower the generation of millenials to manage, save and grow money by breaking down barriers to traditional investing. The Wombat app was launched in the summer of 2019, and the company has already acquired more than 5,000 customers. Moreover, the company was nominated as Best Newcomer for the Robo Investing Awards and received positive press coverage. With the proceeds, Wombat is planning to build a strong customer base, fulfil growth strategy with a significant increase in marketing, product development, and to educate customers about investing.
days to go:
Expired
investment:
£435,717
Living With is a health technology company offering a pocket-friendly and simple patient management application that allows medical professionals treat and track patients remotely. The app aims to revolutionise the way doctors and hospitals access digital tools to treat patients while collecting data for medical device and pharma companies. The company owns Squeezy (a popular paid medical app in the UK) and already has five products in 17 NHS Trusts. Living With also has a contract with one of the world’s greatest medical device companies. Living With will use the proceeds to give 5 data (drug/device) and 50 access customers (clinic/doctor), become HIPAA compliant for the US and to quicken sales and marketing.
days to go:
Expired
investment:
£200,000
MedicSpot is a healthcare company that is aiming to revolutionise healthcare delivery by combining the advantages of online and offline care. The company provides patients at designated hospitals with diagnostic tools like a stethoscope, oximeter, blood pressure monitor and thermometer which, in turn, is connected to the MedicSpot network. Onboard General Physicians (GPs) engage in live sessions with patients, guide them on how to use the tools, and perform a variety of diagnoses like listening to a patient’s heart and lungs, looking down their throat and into their ears, taking their blood pressure and oxygen readings, and measuring their body temperature. The company is also expanding into another subsidiary, Arc Health, which it claims will perform the aforementioned tasks with more efficiency and accuracy. The company will use the investment to increase the number of Medicspot clinics to 1,000, gain further NHS market share, launch a corporate business model and allow international pilots to take place.
days to go:
Expired
investment:
£1,048,396
B-North is creating an SME business bank that will deliver fast decisions with loans being given in two weeks. Its model is formed around strong relationships with both brokers and customers. B-North is in a positive conversation with the British Business Bank for Tier 2 debt, and its FinTech enabled lending platform is excellent. The funds will be used to expand the team and develop the platform. The company also aims at assembling a highly-experienced and ambitious management team supported by a heavyweight board.
days to go:
Expired
investment:
£2,815,350
B-North intends to revolutionise the business lending industry, which is often outdated, impersonal and slow. The fintech company uses some of the most advanced cloud-based technology, coupled with face-to-face relationship teams to get the best lending solutions for borrowers and their businesses. The company is powered by a team with prior experience in starting and scaling challenger banks, and profitability is its focused goal. B-North has submitted the banking licence application, and the result is expected by 2020.
days to go:
Expired
investment:
£2,135,456
gowithYamo aims to make art more accessible to everyone, from art newbies to experienced gallery-goers through its application. Users can collect Yamo points by checking-in to galleries and exchanging them for rewards such as art prints and exhibition tickets from the company's in-app store. gowithYamo provides support to galleries, museums and artists by exposing them to an active community of art lovers. The company also offers custom-built virtual exhibition spaces where artists can show and sell their work to a sizeable digital audience. gowithYamo has collaborated with art entities like Roy's Art Fair, The Other Art Fair, Harlesden High Street, and many others. It has a social media presence of 50,000+ followers. The company will use 30% of the investment to expand across different demographics, 25% to further finetune its virtual exhibition platform, 20% for marketing, and 25% to implement Artificial Intelligence (AI) in the gowithYamo app to help recommend exhibitions to its users.
days to go:
Expired
investment:
£161,105
